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An antigen produced by splicing 
of noncontiguous peptides in the 
reverse order
CD8+ T lymphocytes recognize peptides that are usually 
derived from the degradation of cellular proteins 
and are presented by class I molecules of the major 
histocompatibility complex. In an article published 
in Science, Warren et al.1 describe a human minor 
histocompatibility antigen created by a polymorphism in the 
SP110 nuclear phosphoprotein gene. Th e antigenic peptide 
comprises two noncontiguous SP110 peptide segments 
spliced together in reverse order of that in which they 
occur in the predicted SP110 protein. Th e antigenic peptide 
could be produced in vitro by incubation of precursor 
peptides with highly purifi ed 20S proteasomes. Cutting 
and splicing probably occur within the proteasome by 
transpeptidation. Th e results of the authors’ studies indicate 
that the reordered spliced peptide SLPRGTSTPK derived 
by proteasomal processing of the Arg299 SP110 protein is 
the naturally processed antigen recognized by CTL DRN-7 
and that the splicing reaction occurs in the proteasome by 
transpeptidation involving an acyl-enzyme intermediate. In 
contrast to the two previous examples of spliced peptides, 
the peptide recognized by CTL DRN-7 is produced by 
ligation of two noncontiguous peptide fragments in the 
reverse order. Th e observation that this antigen is expressed 
in some normal cells indicates that peptide splicing is not 
restricted to tumor cells. Th e proteasome, by virtue of its 
proteolytic capacity, participates in the generation of active 
transcription factor domains from inactive precursors, 
controls the levels of numerous regulatory proteins, and 
serves as the major source of peptides recognized by CD8+ T 
cells. Th e ability of the proteasome to splice together peptide 
fragments from a protein in either the initial or the reverse 
order has profound implications for the diversity of peptides 
that can be presented on the cell surface for recognition 
by CD8+ T cells and could also have other unanticipated 
consequences.
A perspective by Nilabh Shastri in the same issue2 
discusses an unexpected mechanism by which cells generate 
these presented antigenic peptides, increasing the breadth 
of proteins generated from the genetic code. Shastri states 
that, irrespective of the still obscure rules for making 
noncontiguous peptides, their existence shows that genetic 
information can be scrambled and yet be useful. Cells do 
not simply discard scrambled peptides and, like defective or 
cryptic translation products, use them to add to the peptide-
bound major histocompatibility complex class I (pMHCI) 
repertoire. Th is view implies that such scramblings are not 
random accidents and would have to be generated in other 
cell types as well. In particular, cells constituting immune 
organs that are responsible for eliminating self-reactive 
T cells must generate the same scrambled peptides. Th is is 
to ensure that autoimmunity will not result from the sudden 
appearance of previously unseen pMHC I in some tissues. 
What fraction of the total pMHC I repertoire represents 
cryptic translation products or spliced and scrambled 
peptides, and whether and how they might be regulated, 
remain important unanswered questions. Nonetheless, 
it is clear, according to Shastri, that peptides from these 
sources are a functional aspect of the antigen presentation 
mechanism that keeps an eye on the genome, including its 
unexpected and unpredictable products. (1Science 2006; 
313: 1444–1447. 2Science 2006; 313: 1398–1399)
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Circulating soluble endoglin as a 
potential test for preeclampsia
Recent work suggests that antiangiogenic proteins 
produced by the placenta are involved in the development 
of preeclampsia and eclampsia. Specifi cally, circulating 
soluble fms-like tyrosine kinase 1 (sFlt1) and endoglin, a 
soluble co-receptor for transforming growth factor-β1, are 
elevated in women with preeclampsia. Also, introduction 
of adenoviruses encoding both sFlt1 and soluble 
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endoglin to rats produced severe hypertension, proteinuria, 
hepatitis, and hemolytic anemia, all manifestations of 
preeclampsia and eclampsia.
Because soluble endoglin acts together with sFlt1 to 
induce a severe preeclampsia-like syndrome in pregnant 
rats, Levine et al. performed a study of healthy nulliparous 
women that included 72 women who had preterm 
preeclampsia (<37 weeks), as well as 480 randomly selected 
women — 120 women with preeclampsia at term (at 
≥37 weeks), 120 women with gestational hypertension, 120 
normotensive women who delivered infants who were small 
for their gestational age, and 120 normotensive control 
subjects who delivered infants who were not small for their 
gestational age. Th ey found that circulating soluble endoglin 
levels increased markedly beginning 2–3 months before 
the onset of preeclampsia (see Figure). Aft er the onset 
of clinical disease, the mean serum level in women with 
preterm preeclampsia was 46.4 ng per ml, compared with 
9.8 ng per ml in controls. Th e mean serum level in women 
with preeclampsia at term was 31.0 ng per ml, compared 
with 13.3 ng per ml in controls. At 17 through 20 weeks of 
gestation, soluble endoglin levels were signifi cantly higher 
in women in whom preterm preeclampsia later developed 
than in controls (10.2 ng per ml versus 5.8 ng per ml), 
and at 25 through 28 weeks of gestation, the levels were 
signifi cantly higher in women in whom term preeclampsia 
developed than in controls (8.5 ng per ml versus 5.9 ng per 
ml). A reliable test to predict preeclampsia has been sorely 
missing. Th e new study by Levine et al., while retrospective 
and cross-sectional, places the measurement of circulating 
proteins that control angiogenesis at the front of potentially 
useful tests to predict preeclampsia and eclampsia in clinical 
practice. (N Engl J Med 2006; 355: 992–1005)
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Role of calcineurin in aquaporin 2 
trafficking: a new model of 
nephrogenic diabetes insipidus
Long-term inhibition of calcineurin with cyclosporin A results 
in polyuria, decreased urine osmolality, and downregulation 
of several aquaporins, including aquaporin 2 (AQP2). It is 
unknown, however, whether cyclosporin A directly alters AQP2 
action or whether it alters urine-concentrating capacity through 
other mechanisms.
AQP2 is a highly glycosylated protein, and it is processed 
through the endoplasmic reticulum and Golgi network, where it 
is folded and targeted to vesicles that are directed to the subapical 
region of the plasma membrane. Water permeability of the inner 
medullary collecting duct cells can then be rapidly regulated by 
the binding of the antidiuretic hormone arginine vasopressin to 
its V2 receptors, located mainly in the basolateral membrane of 
principal cells. Activation of the V2 receptors stimulates adenylyl 
cyclase, leading to elevation of cyclic adenosine monophosphate 
and subsequent activation of protein kinase A (PKA). In turn, 
PKA phosphorylates AQP2, resulting in enhanced accumulation 
of AQP2-bearing vesicles in the plasma membrane, where AQP2 
is inserted by an exocytosis-like process.
In addition to PKA, several factors participate in the normal 
traffi  cking of AQP2, including the Golgi network casein 
kinase, and A kinase anchoring proteins (AKAPs), which 
are scaff olding proteins that facilitate interaction of AQP2 
and PKA. Recent work suggests that the serine/threonine 
phosphatase calcineurin also regulates the traffi  cking of 
AQP2. Calcineurin binds to AKAPs and was identifi ed in 
a complex with AQP2 and an AKAP protein. In addition, 
calcineurin dephosphorylated APQ2 in vitro, and the α isoform 
of calcineurin A subunit (CnAα) and AQP2 colocalize in 
collecting duct principal cells. Finally, calcineurin inhibition 
with cyclosporin A decreased the phosphorylation of AQP2 
and redistributed it away from the apical membrane. To clarify 
the role of CnAα in AQP2 traffi  cking in vivo, Gooch et al. 
analyzed CnAα–/– mice. Th ey found decreased phosphorylation 
of AQP2 in response to vasopressin and signifi cantly less 
AQP2 protein in inner medullary collecting duct vesicles and, 
consequently, in the apical membrane. Instead, AQP2 appeared 
to be retained in an intracellular compartment, consistent with 
a defect in intracellular traffi  cking of the protein. Inhibition 
of calcineurin activity with cyclosporin A recapitulated the 
phenotype of CnAα–/– mice, suggesting that phosphatase 
activity of calcineurin is required for normal AQP2 traffi  cking 
and function. As a result, CnAα–/– mice are a new model of 
nephrogenic diabetes insipidus characterized by an impaired 
response to vasopressin as a result of altered traffi  cking and 
phosphorylation of AQP2. (J Cell Sci 2006; 119: 2468–2476)
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Levels of soluble endoglin according to weeks before the onset of 
preeclampsia.
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